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Duplication of GTF2I Results in
Separation Anxiety in Mice and Humans
Carolyn B. Mervis,1 Joana Dida,2,3 Emily Lam,3 Nicole A. Crawford-Zelli,1 Edwin J. Young,3
Danielle R. Henderson,1 Tuncer Onay,4 Colleen A. Morris,5 Janet Woodruff-Borden,1 John Yeomans,2
and Lucy R. Osborne3,6,7,*
Duplication (dup7q11.23) and deletion (Williams syndrome) of chromosomal region 7q11.23 cause neurodevelopmental disorders with
contrasting anxiety phenotypes. We found that 30% of 4- to 12-year-olds with dup7q11.23 but fewer than 5% of children withWS or in
the general population met diagnostic criteria for a separation-anxiety disorder. To address the role of one commonly duplicated or
deleted gene in separation anxiety, we compared mice that had varying numbers of Gtf2i copies. Relative to mouse pups with one or
two Gtf2i copies, pups with additional Gtf2i copies showed significantly increased maternal separation-induced anxiety as measured
by ultrasonic vocalizations. This study links the copy number of a single gene from 7q11.23 to separation anxiety in both mice and
humans, highlighting the utility of mouse models in dissecting specific gene functions for genomic disorders that span many genes.
This study also offers insight into molecular separation-anxiety pathways that might enable the development of targeted therapeutics.Anxiety disorders are themost common form of psychopa-
thology in childhood, and separation-anxiety disorder
(SAD) is among the most frequent anxiety diagnoses.1
Based on diagnostic interviews conducted with parents,
the prevalence of SAD in children has been estimated as
~2.5%.1,2 Anxiety disorders show strong heritability, but
despite researchers’ considerable efforts to identify genetic
factors, no robust molecular genetic linkages have yet been
demonstrated in humans.3
Williams syndrome4 (WS [MIM 194050]) and duplica-
tion of chromosomal region 7q11.235 (dup7q11.23 [MIM
609757]) are genomic disorders caused by the deletion
and duplication, respectively, of a common 1,500,000 bp
segment spanning 26 genes on human chromosome 7.
These syndromes are both associated with neurocognitive
and behavioral features. Specifically, intellectual disability,
relative strength in language and considerable weakness
in visuospatial construction, social disinhibition, and non-
social anxiety are associated with WS.6–8 In contrast,
dup7q11.23 is associated with speech disorder, language
delay, andbothsocial andnonsocial anxiety.8,9 Thegenomic
overlap and penetrant but contrasting social-anxiety
phenotypes associated with these rare neurodevelopmental
disorders might help establish direct links with genes and
pathways that play a role in particular anxiety disorders.
Anecdotal reports of separation difficulties in young
children with dup7q11.23 (C.B.M., unpublished data)
led us to focus our investigation on separation anxiety.
We measured separation anxiety in children with
dup7q11.23 or WS by using the Anxiety Disorders Inter-
view Schedule: Parent Version10 (ADIS-P) for the Diag-
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Ages 1.5–5 (CBCL 1.5–5).11 All procedures were approved
by the institutional review board at the University of Louis-
ville, and written informed consent was obtained from the
parents of all participants. 7q11.23 deletion or duplication
size was determined by fluorescence in situ hybridization
with labeled probes (purified from bacterial artificial chro-
mosomes [BACs], plasmid artificial chromosomes [PACs],
and cosmids) that bound to metaphase or interphase chro-
mosomes prepared from established lymphoblastoid cell
lines, as previously described.12 Only children with classic
deletions or duplications were included. Demographic
characteristics of the child participants are presented in
Table 1.
The ADIS-P,10 a semistructured interview designed to
assess anxiety and related disorders in children aged 4–16
years, has been used in several studies of children with
WS6,13–15. As part of a larger study of the development of
children with 7q11.23 deletion or duplication, parents
completed the ADIS-P,10 which was used for determining
diagnoses of SAD. The ADIS-P has excellent reliability for
SAD as well as excellent test-retest reliability for the inter-
view.16 Interviewers were licensed clinical psychologists
or advanced clinical-psychology doctoral students who
hadcompleted a rigorous trainingprocedure (seeWoodruff-
Borden et al.15). All interview protocols were reviewed with
the supervising clinical psychologist, who concurred on all
diagnoses of SAD. A child was diagnosed with SAD if he or
she met the DSM-IV diagnostic criteria, including signifi-
cant distress or impairment in functioning.
Parents also completed the CBCL 1.5–5,11 a standardized
questionnaire composed of 99 items describing behavioral,uisville, KY 40292, USA; 2Department of Psychology, Centre for Biological
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Table 2. Proportion of Parental Responses to Item 37a as












2 (very true or
often true)
0.333 0.011
a‘‘Gets too upset when separated from parents.’’emotional, and social problems. For this questionnaire,
parents rate each item on a 3 point scale—0 (not true), 1
(somewhat or sometimes true), or 2 (very true or often
true)—on the basis of their child’s behavior during the
preceding 2 months. Parental response to item 37 (‘‘Gets
too upset when separated from parents’’) was used as
a measure of children’s separation difficulties.
Statistical analyses were performed with SPSS version 20.
Confidence intervals (CIs) for proportions were calculated
with the adjusted Wald method on a CI calculator.
On the basis of the ADIS-P interview, 8 of 27 children
with dup7q11.23 and 9 of 214 children with WS met
DSM-IV criteria for SAD, including the presence of interfer-
ence or distress. Binomial tests comparing these pro-
portions to the proportion of children in the general
population (0.0232) indicated that the proportion of
dup7q11.23-affected children who had SAD (0.296) was
significantly higher than the general-population propor-
tion (p < .0001, dup7q11.23 CI.95 ¼ [0.157, 0.487]). The
proportion of WS-affected children who had SAD (0.042)
did not differ significantly from the general-population
proportion (p ¼ 0.102, WS CI.95 ¼ [0.021, 0.079]). A
comparison of the proportions of children with SAD in
the dup7q11.23 group and the WS group—with the use
of theWS group’s proportion as an estimate of theWS pop-
ulation value—indicated that SAD was significantly more
common among children with dup7q11.23 than among
children with WS (p < 0.0001).
To provide a more conservative estimate of possible
differences in prevalence of SAD between children with
dup7q11.23 orWS and children in the general population,
we compared the prevalence rates for the participants in
our study to the prevalence rate reported by Leyfer and
her colleagues6 for 84 typically developing siblings of chil-
dren with WS (0.036). SAD was determined on the basis of
parental interviews with the use of the ADIS-P, the same
diagnostic interview that was used for assessing SAD for
the children with dup7q11.23 or WS in the present study.
A Fisher exact test indicated that the prevalence of SADwas
significantly higher for children with dup7q11.23 than forThe AmericLeyfer et al.’s typically developing sample (p ¼ 0.005).
However, there was no difference in prevalence of SAD
between children with WS and the children in Leyfer
et al.’s typically developing sample (p ¼ 1.00).
Parental responses to item 37 (addressing separation
difficulty) on the CBCL 1.5–511 are shown in Table 2. A
binomial test indicated that when difficulty with separa-
tion was defined as a score of 2 on item 37, the proportion
of dup7q11.23-affected children who had difficulty sepa-
rating from their parents (0.333) was significantly higher
than the proportion of children with WS (0.011) (p <
.0001, dup7q11.23 CI.95 ¼ [0.161, 0.564]). Similarly,
when difficulty with separation was defined as a score of
1 or 2 on item 37, the dup7q11.23 proportion (0.611)
was significantly higher than the WS proportion (0.182)
(p < .0001, dup7q11.23 CI.95 ¼ [0.384, 0.798]). In both
these analyses, the WS group’s proportion was used as an
estimate of the WS population value.
To test the hypothesis that SAD and separation difficul-
ties in dup7q11.23 might be linked with dosage of a single
gene, we generated mice with decreased or increased
genomic copy number of general transcription factor 2I
(Gtf2i [MIM 601679]), a gene from the commonly deleted
or duplicated region. Gtf2i is highly expressed in the
prenatal and postnatal developing brain17,18 and acts as
both a transcriptional activator19 and a regulator of intra-
cellular calcium levels.20 In mouse pups, separation
anxiety can be assessed through ultrasonic vocalizations
(USVs).21 Mouse pups emit 50–120 kHz USVs in response
to maternal separation, as well as to other stressful
stimuli.21 These pup USVs are believed to increase
mother-infant social contact after separation and prompt
retrieval by the mother. Maternal separation-induced
USVs are strongly associated with anxiety and are an etho-
logically validated measure for preclinical characterization
of anxiolytic drugs.22
Mice with a genomic duplication ofGtf2iwere generated
with Cre-loxP technology in combination with an in vivo
breeding strategy (Figure 1A). Independent mouse lines
with loxP sites at the desired endpoints were generated:
Gtf2ird1Gt(XS0608)Wtsi was created as described previ-
ously,23 and Gtf2i3
0UTRloxP was created by gap-repair target-
ing with clones from a 50/30 phage library.24 The targetingan Journal of Human Genetics 90, 1064–1070, June 8, 2012 1065
Figure 1. Generation of Mice with
Decreased or Increased Gtf2i Dosage
(A) Schematic representation of the gener-
ation of mice with duplication of Gtf2i.
XS0608 contains a loxP site inserted into
intron 4 of Gtf2ird1, whereas the 30UTR-
loxP line contains a loxP site downstream
of the last coding exon of Gtf2i. Recombi-
nation between the loxP sites in vivo re-
sulted in duplication of the entire Gtf2i
gene in the male gamete of transloxer
male mice carrying both loxP sites in
trans, as well as a Cre transgene under
the control of the Sycp1 promoter. Dupli-
cated chromosomes were transmitted to
offspring upon crossing with wild-type
(WT) females. The centromere of mouse
chromosome 5 is represented by the circle
at the left end of each diagram. LoxP sites
are represented by a shaded triangle.
(B) Immunoblot analysis of GTF2I from
whole brain of P8 mice with the use of a
polyclonal antibody (610943, BD Bio-
sciences, Franklin Lakes, NJ). GAPDH
(ab36840, Abcam, Cambridge, MA) was
used as a control for protein loading
(50 mg per lane). Representative blots
from three independent pups are shown.
(C) A graph (createdwith Image J [National
Institutes of Health]) comparing the
densitometric measurement of GAPDH
with that of GTF2I in whole brain of P8
mice. Data are represented as mean 5
SEM (n ¼ 3 for each group).vector included a 9 kb Gtf2i fragment spanning from exon
25 to the 30UTR, resulting in the duplication of these exons
downstream of Gtf2i and the insertion of a loxP site after
recombination between the vector and the endogenous
locus. Aggregation of correctly targeted embryonic stem
cells with morula-stage embryos generated chimeras,
which were bred to CD1 females for the production of
Gtf2iþ/3
0UTRloxP mice.
To generate the Gtf2i duplication, Gtf2ird1Gt(XS0608)Wtsi
mice were crossed with Gtf2i3
0UTRloxP mice that also carried
a Cre transgene under the control of the Sycp1 promoter
(Sycp1-Cre).25 ‘‘Transloxer’’ males carrying both the
Gtf2ird1Gt(XS0608)Wts and Gtf2i3
0UTRloxP alleles as well as
the Sycp1-Cre transgene were crossed with CD1 females
(Figure 1A), and the offspring were screened by PCR with
primer set GtDup, which generated a 250 bp amplicon
specific for the duplication. We used quantitative PCR
(qPCR) to characterize mice carrying the duplication
(Gtf2iþ/Dup) in order to identify changes in copy number
of Gtf2i exons 5 and 30. Primer sequences are shown in1066 The American Journal of Human Genetics 90, 1064–1070, June 8, 2012Table S1, available online. We gener-
ated Gtf2iþ/Dup mice, Gtf2iDup/Dup
mice, and wild-type (WT) litter-
mates through the intercrossing of
Gtf2iþ/Dup mice tominimize variation
of the maternal environment and
provide within-litter controls.Gtf2iþ/mice contain a genetrap insertion within intron
3 of Gtf2i, and this insertion creates a null allele
(Gtf2iGt(YTA365)Byg/þ).26 Gtf2i/ mice died during embryo-
genesis. Mice were generated by injection of Gt(YTA365)
Byg embryonic stem cells into C57BL/6 blastocysts, were
maintained on a CD1 background, and had reached the
third generation of backcrossing at the time of these exper-
iments. We generated Gtf2iþ/ mice and WT littermates
through the intercrossing of Gtf2iþ/ mice to minimize
variation of the maternal environment and provide
within-litter controls. All procedures were approved by
the University of Toronto Animal Care Committee and
were carried out in compliance with the Canadian Council
on Animal Care guidelines.
An approximate 50% reduction in Gtf2i mRNA expres-
sion and protein levels was seen in whole adult brain tissue
from Gtf2iþ/ mice, and an approximate 50% increase in
Gtf2i mRNA expression and protein levels was seen in
brain tissue from Gtf2iþ/Dup mice (Figures 1B and 1C).
Expression of flanking genes Gtf2ird1 (MIM 604318) and
Figure 2. Number of USVs Produced by Mouse Pups during
Maternal-Separation Period
(A) Box plots show the distribution of USVs produced over the
4 min testing period as a function of genotype. Data are repre-
sented as the median plus the upper and lower quartiles. The
lowest and highest observations are indicated by whiskers. The
outlier is indicated by an asterisk.
(B) Median number of USVs produced by P8 mouse pups during
eachminute of the 4minmaternal-separation period as a function
of genotype.Clip2 (MIM 603432) was assessed by real-time PCR as
described previously27 and was found to be unchanged
(data not shown).
We recorded ultrasonic vocalization in mouse pups with
one (Gtf2iþ/, n ¼ 11), two (WT, n ¼ 49), three (Gtf2iþ/Dup,
n ¼ 30), or four (Gtf2iDup/Dup, n ¼ 18) Gtf2i copies during
a 4 min separation from their mother. Mice were housed
with access to food and water ad libitum and were on
a 12 hr light/dark cycle throughout the experiments.
Pups came from litters of between 5 and 13 animals and
lived with both parents in their home cage. Date of birth
was considered postnatal day (P) 0, and pups were tattooed
for identification on the hind paw at P6 by the subcuta-The Americneous insertion of dye near the end of the toe with the
use of capillary action from a 20G needle. Data were pooled
across all male and female pups within genotype groups
and were collapsed across litters as in previously reported
studies.28
Maternal separation-induced USVs were recorded on P8
between 10 am and 6 pm. The family cage containing the
litter of pups and their parents was transported to the
procedure room, illuminated by two 40 W red bulbs.
Each pup was separated from the litter one at a time in
random order and placed in a shallow plastic beaker
(height ¼ 6 cm, diameter ¼ 4 cm) in a sound-attenuating
chamber (40 3 25 3 30 cm). The ultrasound detector
D1000X (Pettersson Elektronik AB, Uppsala, Sweden) was
suspended 12 cm above the floor of the beaker. After
a 5 s habituation period, USV emissions for the next
4 min at a sampling frequency of 250 kHz were recorded.
The primary dependent variable was the total number of
USVs. Immediately after USV recording, the pups were
weighed and returned to the home cage. Mean weight
was 5.45 g (standard deviation [SD] ¼ 0.69) for the
Gtf2iþ/ group, 5.29 g (SD ¼ 0.87) for the Gtf2iþ/þ group,
5.67 g (SD ¼ 0.99) for the Gtf2iþ/Dup group, and 5.56 g
(SD¼ 0.98) for theGtf2iDup/Dup group, indicating a healthy
nutritional status for each group. The results of a Kruskal-
Wallis test indicated that body weight did not differ signif-
icantly as a function of genotype (p ¼ 0.36). Accordingly,
body weight was not included as a factor in subsequent
analyses.
Approximately half of the pups were tested in beakers
with clean materials (cotton pads), and half were tested
with soiled cotton nest material in counterbalanced orders.
A preliminary Mann-Whitney U-test indicated that the
distributions of the median number of USVs produced by
mouse pups during the 4 min separation period did not
differ significantly as a function of bedding type (nest or
clean) (p ¼ 0.82). Accordingly, bedding type was not
included as a factor in subsequent analyses. Spectrographs
(20–125 kHz) were generated by discrete Fourier transfor-
mation (256 bins) and analyzed with Avisoft SASLab Pro
Software v.4.39 (Avisoft Bioacoustics, Berlin, Germany).
Sonograms were analyzed by a trained coder who was
blind to genotype. A second trained coder, also blind to
genotype, independently analyzed the sonograms of two
litters (two Gtf2iþ/, six Gtf2iþ/þ, three Gtf2iþ/Dup, and
four Gtf2iDup/Dup). The means and SDs for the total number
of USVs counted by the two coders for the 4min separation
period were very similar (coder 1: mean ¼ 305.87, SD ¼
197.03; coder 2: mean ¼ 307.60, SD ¼ 195.98), and reli-
ability was excellent (r ¼ 0.999, p < 0.0001).
Because of violations of the assumptions of normality
and homogeneity of variance and because of unequal
numbers of mouse pups across genotypes, nonparametric
statistics were used for the analysis of the mouse USV
data. The distributions of the numbers of USVs produced
during the 4min separation period are indicated separately
for each genotype in Figure 2A. The median number ofan Journal of Human Genetics 90, 1064–1070, June 8, 2012 1067
USVs produced in each minute of the separation period
as a function of genotype is shown in Figure 2B. A
Kruskal-Wallis test indicated a significant difference
among genotypes in the median number of USVs pro-
duced over the 4 min period (standardized test statistic ¼
15.95, p < 0.001). Follow-up stepwise-stepdown tests
identified two homogeneous subsets. Subset 2 (Gtf2iþ/Dup
and Gtf2iDup/Dup genotypes) produced significantly more
USVs than did subset 1 (Gtf2iþ/ and Gtf2þ/þ genotypes)
(p < 0.05).
The production of USVs inmouse pups can be influenced
by both genetic and environmental factors, including cold
temperatures, odors, handling, and maternal-pup interac-
tions.21 The results from our study argue strongly in favor
of a genetic cause of separation-induced USVs in our mice
given that maternal genotype, handling, and odors were
controlled across genotypes. As shown in Figure 2B, USVs
in the Gtf2iþ/Dup and Gtf2iDup/Dup mice decline over the
time of separation (excluding temperature as the basis for
genotype differences in the number of USVs produced),
demonstrating that the initial separation is key to the
increased production of USVs.
USVs can be altered in mice through the modulation of
several different systems, including the serotonergic,
cholinergic, GABAergic, and opiate systems. In particular,
selective serotonin inhibitors (SSRIs) have been shown to
attenuate production of USVs in mouse pups.28 Interest-
ingly, SSRIs are the first-line medication for SAD, and
indeed, for most anxiety disorders in children.1,29
Although SSRIs are generally well tolerated, the response
rate in children with SAD has not been well studied, and
the available data from randomized placebo-controlled
trials suggest that it is quite variable.29 Comorbid diag-
noses are also very common in children with anxiety
disorders, and it is not clear which groups benefit most
from specific medications.29 SSRI treatment in children
with dup7q11.23 has not been formally tested, but identi-
fication of GTF2I downstream molecular pathways that
mediate separation anxiety will allow the development
and use of alternative, pathway-directed medications.
GTF2I has been shown to act as both a basal transcrip-
tional factor and a transcriptional coactivator through
binding to elements within the promoter of a number of
genes.19 GTF2I is able to promote transcription upon
phosphorylation by Src and subsequent translocation to
the nucleus30 and might provide a link between signal
transduction and gene expression. Of genes shown to be
regulated by GTF2I, only c-FOS (MIM 164810) is known
to function in the brain, where it combines with c-JUN
(MIM 165160) to form the activity-dependent transcrip-
tion factor activator protein 1.31
GTF2I is also able to negatively regulate agonist-induced
calcium entry into cells through interfering with the
transport of transient receptor potential channel 3
(TRPC3 [MIM 602345]) to the plasma membrane by
phospholipase C-g20. Although no direct link between
calcium and anxiety has been demonstrated, aberrant1068 The American Journal of Human Genetics 90, 1064–1070, Juneregulation of intracellular calcium levels might affect
downstream signaling pathways such as those that depend
on Ca2þ/calmodulin-dependent protein kinases (CaMKs).
Inmice, increased levels of CaMK2A (MIM 114078), which
is activated in response to an increase in the intracellular
concentration of Ca2þ, lead to increased anxiety.32
Deletion of CaMK4 (MIM 114080), which phosphorylates
cyclic-AMP response element-binding protein (CREB [MIM
123810]) and CRE modulator (CREM [MIM 123812]),
causes reduced anxiety in mice.33 CREB and CREM are
both activity-dependent regulators of the transcription of
multiple genes, including those involved in emotional
behavior.34,35 Interestingly, SSRIs increased expression of
CREB protein in rats, but other medications such as
antipsychotics and opioids did not.36
Anxiety disorders are common, disabling, and show
comorbidity with depression, substance-abuse disorders,
and other serious psychiatric disorders.29 Despite evidence
of a strong genetic component underlying the etiology of
many anxiety disorders, targeted and genome-wide
association studies have identified only a few linked chro-
mosomal regions,most of which have not been easily repli-
cated. Rare disorders, such as dup7q11.23, provide more
easily identifiable genetic causes that can be used as a start-
ing point for identifying the neuromolecular underpin-
nings of anxiety disorders. Even if rare and common forms
of anxiety are caused by different genetic alterations, these
alterations might produce downstream effects in specific
biological pathways or neural circuits that are shared.
Thus, identifying thegenes strongly associatedwith specific
anxiety phenotypes in rare disorders should lead to a better
understanding of pathophysiology and provide a starting
point for the identification of genes and pathways that
cause these common disorders in the general population.
In summary, the association between a major anxiety
disorder and change in copy number of a single gene
provides a starting point for understanding the molecular
basis of anxiety. In doing so, the research reported in this
paper demonstrates the promise of the dissection of rare
genomic disorders for unraveling the genetic complexity
of common disease.Supplemental Data
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